Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering a composition comprising an antiviral agent in a dosing regimen that achieves a multiphasic serum concentration profile of the antiviral agent. The dosing regiment includes dosing events that are less frequent than with currently available hepatitis therapies. The multiphasic antiviral agent serum concentration profile that is achieved using the methods of the invention effects an initial rapid drop in viral titer, followed by a further decrease in viral titer over time, to achieve a sustained viral response
1 . A method for treating hepatitis C virus infection in an individual, the method comprising:
administering a composition comprising interferon-α (IFN-α) in an amount effective to achieve a first serum concentration of IFN-α that is at least about 80% of the maximum tolerated dose (MTD) within a first period of time of about 24 to 48 hours, followed by a second concentration of IFN-α that is about 50% or less than the MTD, which second concentration is maintained for a second period of time of at least seven days.
2 . The method of claim 1 , wherein a sustained viral response is achieved.
3 . The method of claim 1 , further comprising administering IFN-γ for a period of from about 1 day to about 14 days before administration of IFN-α.
4 . The method of claim 1 , wherein IFN-α is administered in a depot.
5 . The method of claim 1 , wherein IFN-α is administered by continuous infusion.
6 . The method of claim 5 , wherein said continuous infusion administration is achieved with a pump.
7 . The method of claim 1 , wherein IFN-α is administered by a single subcutaneous injection followed by continuous infusion using a pump.
8 . A method of treating hepatitis C virus infection in an individual, the method comprising:
administering IFN-α in a dosing regimen comprising a first phase and a second phase, wherein, in the first phase, a first serum concentration of IFN-α is achieved that is at least about 80% of the maximum tolerated dose (MTD) within a first period of time of about 24 hours, wherein in the second phase, the ratio of the highest IFN-α serum concentration to the lowest serum IFN-α concentration, measured over any 24-hour period during the second phase, is less than 3, and wherein the highest concentration of IFN-α during the second phase is about 50% or less than the MTD.
9 . The method of claim 8 , wherein the ratio of the highest IFN-α serum concentration to the lowest serum IFN-α concentration, measured over any 24-hour period during the second period of time is about 1.
10 . A method for treating hepatitis C virus infection in an individual, the method comprising:
administering a composition comprising consensus interferon-α (CIFN) in an amount effective to achieve a first serum concentration of CIFN that is at least about 80% of the maximum tolerated dose (MTD) within a first period of time of about 24 hours, followed by a second concentration of CIFN that is about 50% or less than the MTD, which second concentration is maintained for a second period of time of at least seven days.
11 . A method of treating hepatitis C virus infection in an individual, the method comprising:
administering consensus IFN-α (CIFN) in a dosing regimen comprising a first phase and a second phase, wherein, in the first phase, a first serum concentration of CIFN is achieved that is at least about 80% of the maximum tolerated dose (MTD) within a first period of time of about 24 hours, wherein in the second phase, the ratio of the highest CIFN serum concentration to the lowest serum CIFN concentration, measured over any 24-hour period during the second phase, is less than 3, and wherein the highest concentration of CIFN during the second phase is about 50% or less than the MTD.
12 . A method of treating hepatitis C virus infection in an individual, the method comprising:
administering IFN-α in a dosing regimen comprising a first phase and a second phase, wherein, in the first phase, a first serum concentration C1max of IFN-α is achieved within a first period of time of about 24 hours, wherein in the second phase, a Csus is achieved that is about 50% of C1max or less, and wherein the area under the curve, defined by IFN-α serum concentration as a function of time, during any 24-hour time period in the second phase is no greater than the area under the curve of day 2 to day 3 as shown in FIG. 2 .
13 . A method of treating hepatitis C virus infection in an individual, the method comprising:
administering consensus IFN-α (CIFN) in a dosing regimen comprising a first phase and a second phase, wherein, in the first phase, a first serum concentration C1max of CIFN is achieved within a first period of time of about 24 hours, wherein in the second phase, a Csus is achieved that is about 50% of C1max or less, and wherein the area under the curve, defined by CIFN serum concentration as a function of time, during any 24-hour time period in the second phase is no greater than the area under the curve of day 2 to day 3 as shown in FIG. 2 .